Advertisement Pharmaceutical Business review - Page 4 of 5233 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 14, 2025

FDA clears PDS Biotechnology’s Versamune MUC1 combo for mCRC

The US Food and Drug Administration (FDA) has granted clearance for PDS Biotechnology's investigational new drug (IND) application to assess Versamune MUC1 plus PDS01ADC for the treatment of unresectable, metastatic colorectal carcinoma (mCRC).

Continue
The trial will assess the combo in individuals with recurrent or mCRC. Credit: Louis Reed on Unsplash.
March 13, 2025

LGM Pharma to expand manufacturing capabilities with $6m investment

The investment is expected to improve the site's capacity to produce prescription drug products. Credit: Hal Gatewood on Unsplash.
March 12, 2025

Aprea and MD Anderson sign agreement for APR-1051

The therapy is being evaluated in the ongoing multi-centre Phase I trial. Credit: Diane Serik on Unsplash.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Vivus’ Qsymia gains market approval in UAE for obesity treatment
  2. UK MHRA approves Vertex’s Alyftrek for cystic fibrosis
  3. Relief and Renexxion terminate merger talks
  4. CordenPharma announces $1bn investment in peptide development and production
  5. FairJourney acquires Charles River’s San Francisco site

PRESS RELEASES

Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation